Cypher's Sirolimus-Eluting Stent Outperforms Taxus at 15 Months
October 23, 2007 – Patients who received the CYPHER Sirolimus-eluting coronary stent had a lower risk of stent thrombosis and were less likely to need another procedure at the same lesion site (target lesion revascularization) than patients who received a Taxus stent, according to an analysis of 15-month data from the Western Denmark Heart Registry presented at TCT 2007.
The differences between the CYPHER stent and the Taxus in terms of definite stent thrombosis showed that patients who received the Taxus stent were 55 percent more likely to develop definite stent thrombosis than patients who received the CYPHER stent. Taxus patients were also 49 percent more likely to develop definite/probably/possible stent thrombosis than patients who received a CYPHER stent. Plus, the Taxus stent patients were 32 percent more likely to need a repeat procedure compared with patients who received the CYPHER stent.
For more information: www.cypherstent.com
More like this
- Drug-Eluting, Bare-Metal Stents Yield Similar Mortality Rates
- Study Shows Significant Reduction in Blood Clots and Reintervention With Cypher Sirolimus-eluting Coronary Stent
- Stent Reduces MACE by 55 Percent
- CYPHER DES Shows Sustained Benefits Compared to BMS in Six-Year Trial
- Boston Scientific, Cordis, Present Data to FDA